GCG and familial pancreatic carcinoma: In addition, FDA and EMA independently evaluated the safety data from postmarketing reports of pancreatitis and pancreatic cancer in patients using incretin-based drugs, analysing both animal and clinical information available, and concluded that a causal association between incretin-based drugs and pancreatitis or pancreatic cancer cannot be established with the current data; however, FDA and the EMA have not reached a final conclusion regarding such a causal relationship, and both agencies will continue to investigate the safety signal [230].